Sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 21, Issue 3, 2005, Pages 348-353

  MacFaul, George R ^a   Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; Orthotopic liver transplantation; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; BILE DUCT INJURY; BILIARY TRACT CANCER; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; GENETIC HETEROGENEITY; HEPATOBILIARY DISEASE; HEPATOBILIARY SYSTEM; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; SCLEROSING CHOLANGITIS; SURVIVAL; TREATMENT OUTCOME;

CHOLANGITIS, SCLEROSING; HUMANS;

EID: 17844363472     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000155359.43763.cc     Document Type: Review

References (36)

1. Yang X, Cullen SN, Li JH, et al. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004; 40:375-379.
2. Wiencke K, Louka AS, Spurkland A, et al. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis. J Hepatol 2004; 41:209-214.
3. Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001; 121:124-130.
4. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127:261-274.
5. Pauli-Magnus C, Kerb R, Fattinger K, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004; 39:779-791.
6. Panasiuk A, Prokopowicz D, Zak J, et al. Lymphocyte subpopulations in peripheral blood in primary sclerosing cholangitis. Hepatogastroenterology 2004; 51:1289-1291.
7. Kingham J, Kochar N, Gravenor M. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126:1929-1930. This report describes the epidemiology and outcome of PSC in a District General population in South Wales.
8. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125:1364-1369.
9. Rodrigues F, Davies EG, Harrison P, et al. Liver disease in children with primary immunodeficiencies. J Pediatr 2004; 145:333-339.
10. Takikawa H, Takamori Y, Tanaka A, et al. Analysis of 388 cases of primary sclerosing cholangitis in Japan: presence of a subgroup without pancreatic involvement in older patients. Hepatol Res 2004; 29:153-159.
11. Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004; 16:585-592.
12. Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004; 53:973-979.
13. Mitchell SA, Thyssen M, Orchard TR, et al. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002; 51:567-573.
14. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39:204-210.
15. Bjornsson E, Simren M, Olsson R, et al. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2004; 39:961-968.
16. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523-526. This report shows a reduced risk for the development of cholangiocarcinoma in comparison with previous studies.
17. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321-327.
18. Koopmann J, Thuluvath PJ, Zahurak ML, et al. Mac-2 binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004; 101:1609-1615. This interesting paper suggests the use of a novel biliary marker in diagnosis of cholangiocarcinoma, especially in combination with CA 19-9.
19. Talwalkar JA, Angulo P, Johnson CD, et al. Cost-minimalisation analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004; 40:39-45.
20. Hirche TO, Russler J, Braden B, et al. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis 2004; 19:586-594.
21. Silva AC, Friese JL, Hara AK, et al. MR cholangiopancreatography: improved ductal distension with intravenous morphine administration. Radiographics 2004; 24:677-687.
22. Macchi V, Floreani A, Marchesi P, et al. Imaging of primary sclerosing cholangitis: preliminary results of new non-invasive techniques. Dig Liver Dis 2004; 36:614-621.
23. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121:900-907.
24. Rost D, Rudolph G, Kloeters-Plachky P, et al. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 50:693-698. This paper confirms increasing biliary enrichment with increasing UDCA dosage, reaching a plateau at 22 to 25 mg/kg.
25. Sterling RK, Salvatori JJ, Luketic VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004; 20:943-949.
26. Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2004; CD004036.
27. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sec 2004; 49:1-4.
28. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151-156.
29. Bjornsson E, Lindquist-Ottosson J, Asztely M, et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:502-508.
30. Yamamoto T, Hirohashi K, Kubo S, et al. Surgery for segmental primary sclerosing cholangitis. Hepatogastroenterology 2004; 51:668-671.
31. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003; 38:1176-1183.
32. Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40:815-822. This intriguing study found that not having received UDCA was an independent predictor for the development of hepatobiliary malignancy in patients with PSC.
33. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124:889-893.
34. Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003; 35:2431-2434.
35. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004; 99:538-542.
36. Welsh FK, Wigmore SJ. Roux-en-Y choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation 2004; 27:602-604.